← Leaderboards
Michael C Jensen
City Of Hope National Medical Center
$5,983,472
Attributed
$8,747,509
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $733K · FY2005–18$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$8,747,509 · 11
By mechanism
R01$6,577,590 · 2
P50$1,146,104 · 2
R21$662,400 · 1
M01$361,415 · 5
P01$0 · 1
Top collaborators
- Stanley R Riddell10 shared
Most similar at City Of Hope National Medical Center
Same institution · by research overlap
- Andrew A. Raubitschek$10,642,515
- Paul Yazaki$5,458,492
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteCellsSafetyCd19 GeneTumorEngineeringRelapseClinical TrialsAdoptive TransferGeneticCd8b1 GeneImmunotherapyModificationIn VitroIn VivoNeoplastic CellChemotherapyB-LymphocytesHematopoietic Stem Cell TransplantationResponseStem Cell TransplantT Memory CellMemoryDesign
Grant awards (34)
Targeted therapy of B cell malignances with CAR-T cells of defined composition$560,424
R01 · FY2018 · CA
Targeted therapy of B cell malignances with CAR-T cells of defined composition$560,424
R01 · FY2017 · CA
Targeted therapy of B cell malignances with CAR-T cells of defined composition$560,424
R01 · FY2016 · CA
Targeted therapy of B cell malignances with CAR-T cells of defined composition$560,424
R01 · FY2015 · CA
Adoptive T Cell Therapy For Non-Hodgkin Lymphoma$172,534
P50 · FY2015 · CA · contact PI
Targeted therapy of B cell malignances with CAR-T cells of defined composition$579,424
R01 · FY2014 · CA
Adoptive T Cell Therapy For Non-Hodgkin Lymphoma$151,912
P50 · FY2014 · CA · contact PI
Targeted therapy of ALL with gene-modified central memory T cells$508,741
R01 · FY2013 · CA
Adoptive T Cell Therapy For Non-Hodgkin Lymphoma$211,970
P50 · FY2013 · CA · contact PI
Targeted therapy of ALL with gene-modified central memory T cells$542,633
R01 · FY2012 · CA
Adoptive T Cell Therapy For Non-Hodgkin Lymphoma$180,825
P50 · FY2012 · CA · contact PI
Targeted therapy of ALL with gene-modified central memory T cells$543,264
R01 · FY2011 · CA
Targeted therapy of ALL with gene-modified central memory T cells$560,754
R01 · FY2010 · CA
Targeted therapy of ALL with gene-modified central memory T cells$551,563
R01 · FY2009 · CA
Cellular Immunotherapy for Follicular Lymphoma Using CD19- Specific T-Cells$104,098
P50 · FY2008 · CA · contact PI
CLINICAL TRIAL: PILOT/FEASIBILITY STUDY TO EVALUATE THE SAFETY OF CELLULAR$57,683
M01 · FY2008 · RR · contact PI
Cellular Immunotherapy for Follicular Lymphoma Using CD19- Specific T-Cells$100,648
P50 · FY2007 · CA · contact PI
PILOT FEASIBILITY AND SAFETY STUDY OF CELLULAR IMMUNOTHERAPY FOR RECURRENT/REF$81,406
M01 · FY2007 · RR · contact PI
PILOT/FEASIBILITY STUDY TO EVALUATE THE SAFETY OF CELLULAR$36,973
M01 · FY2007 · RR · contact PI
CELLULAR IMMUNOTHERAPY OF GLIOBLASTOMA MULTIFORME USING AN$7,754
M01 · FY2007 · RR · contact PI
Glioma Immunotherapy Usingengineered T-Cells$344,315
R01 · FY2006 · CA · contact PI
CD19 Specific Immunotherapy for Follicular Lymphoma$54,630
P50 · FY2006 · CA · contact PI
PILOT FEASIBILITY AND SAFETY STUDY OF CELLULAR IMMUNOTHERAPY FOR RECURRENT/REF$24,277
M01 · FY2006 · RR · contact PI
Glioma Immunotherapy Usingengineered T-Cells$352,600
R01 · FY2005 · CA
PILOT FEASIBILITY AND SAFETY STUDY OF CELLULAR IMMUNOTHERAPY FOR RECURRENT/REF$147,972
M01 · FY2005 · RR
CD19 Specific Immunotherapy for Follicular Lymphoma$85,996
P50 · FY2005 · CA
Glioma Immunotherapy Using engineered T-Cells$352,600
R01 · FY2004 · CA
CD19 Specific Immunotherapy for Follicular Lymphoma$83,491
P50 · FY2004 · CA
Pilot Feasibility and Safety Study of Cell Immunotherapy$5,350
M01 · FY2004 · RR
Cellular Immunotherapy for Neuroblastoma With CTL clones$326,025
R21 · FY2002 · CA
TARGETING MALIGNANT B CELLS IN LYMPHOMA AND LEUKEMIA$0
P01 · FY2002 · CA
Cellular Immunotherapy for Neuroblastoma With CTL clones$336,375
R21 · FY2001 · CA
TARGETING MALIGNANT B CELLS IN LYMPHOMA AND LEUKEMIA$0
P01 · FY2001 · CA
TARGETING MALIGNANT B CELLS IN LYMPHOMA AND LEUKEMIA$0
P01 · FY2000 · CA